Clinical Trials/NCT00718809

NCT00718809TerminatedPhase 2

Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)

National Cancer Institute (NCI)2 sites in 1 country21 target enrollmentStarted: June 2008Last updated: June 10, 2015

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 2
Status: Terminated
Sponsor: National Cancer Institute (NCI)
Enrollment: 21
Locations: 2
Primary Endpoint: Objective Response Rate (Complete and Partial Response)

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

This phase II trial is studying how well saracatinib works in treating patients with relapsed or refractory thymoma or thymic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth

Detailed Description

PRIMARY OBJECTIVES:

I. To evaluate the objective response rate (complete response and partial response) in patients with relapsed or refractory thymoma or thymic carcinoma treated with AZD0530.

SECONDARY OBJECTIVES:

I. To evaluate the toxicity of AZD0530 in these patients. II. To evaluate the progression-free survival of these patients. III. To evaluate the overall survival of these patients. IV. To evaluate the disease control rate, defined as complete response, partial response, and stable disease, in these patients.

OUTLINE: This is a multicenter study.

Study Design

Study Type: Interventional
Allocation: Na
Intervention Model: Single Group
Primary Purpose: Treatment
Masking: None

Eligibility Criteria

Ages: 18 Years to — (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Histologically confirmed invasive thymoma or thymic carcinoma, meeting the following criteria:
•Relapsed or refractory disease
•Metastatic, unresectable disease
•Locally invasive disease allowed provided it is not resectable and has been previously treated
•Progressive disease
•Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques or >= 10 mm by spiral CT scan
•Must have received >= 1 prior chemotherapy regimen
•No active brain metastases
•Patients with previously treated brain metastases (surgical resection or radiotherapy) are eligible provided they have documented stable brain disease for >= 1 month after completion of therapy and are asymptomatic
•ECOG performance status 0-2
•Leukocytes >= 3,000/mm^3
•ANC >= 1,500/mm^3
•Platelet count >= 100,000/mm^3
•Hemoglobin > 9 g/dL
•Serum bilirubin < 2.0 times upper limit of normal (ULN)
•Transaminases =< 2.5 times ULN (< 5.0 times ULN if liver metastasis is present)
•Serum creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min
•Urine protein:creatinine ratio < 0.5 OR urine protein < 1,000 mg by 24-hour urine collection
•QTc < 460 msec
•Not pregnant or nursing
•Negative pregnancy test
•Fertile patients must use effective contraception during and for 30 days after completion of study treatment
•No known history of allergic reactions attributed to compounds of similar chemical or biological composition to AZD0530
•No other malignancies within the past 3 years, except curatively treated in situ carcinoma of the cervix or completely resected nonmelanoma skin cancer
•No concurrent active malignancies other than thymic malignancy
•No condition that impairs the ability to swallow AZD0350 tablets (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease)
•No cardiac dysfunction including, but not limited to, any of the following:
•Symptomatic congestive heart failure
•Unstable angina pectoris
•Cardiac arrhythmia
•History of ischemic heart disease
•Myocardial infarction within the past year
•No QTc prolongation or other significant ECG abnormalities
•No poorly controlled hypertension (i.e., systolic blood pressure [BP] ≥ 150 mm Hg or diastolic BP ≥ 95 mm Hg)
•No evidence of severe or uncontrolled systemic conditions that would make it undesirable to participate in the study or that would jeopardize compliance with the study, including any of the following:
•Severe hepatic impairment
•Interstitial lung disease (bilateral, diffuse, or parenchymal lung disease)
•Unstable or uncompensated respiratory condition
•Unstable or uncompensated cardiac condition
•No uncontrolled illness including, but not limited to, any of the following:
•Ongoing or active infection
•Mental health issues or social circumstances that would limit compliance with study requirements
•No prior src inhibitors
•At least 4 weeks since prior systemic therapy (6 weeks for carmustine or mitomycin C)
•At least 8 weeks since prior immunotherapy
•At least 4 weeks since prior octreotide
•Concurrent octreotide for pure red cell aplasia allowed provided patient continues on the same dose and schedule, has had a response to this drug, and has demonstrated progressive thymoma by radiography or physical exam
•At least 4 weeks since prior surgery and recovered
•At least 4 weeks since prior investigational agents
•At least 4 weeks since prior radiotherapy to measurable disease sites (2 weeks for palliative radiotherapy to metastatic sites) and recovered
+4 more not shown

Exclusion Criteria

Not provided

Arms & Interventions

Arm I

Experimental

Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Intervention: saracatinib (Drug)

Outcomes

Primary Outcomes

Objective Response Rate (Complete and Partial Response)

Time Frame: Up to 5 years

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. The objective response rate will be reported by each disease classification. The percent of patients having an objective response (complete or partial response) will be estimated with a 95% exact binomial confidence interval for the percent of patients receiving drug. Note: there were no objective responses in this trial.

Secondary Outcomes

Disease Control Rate(Up to 5 years)
Progression-free Survival(Time from the date of registration to the first reported outcome event, assessed up to 5 years)
Expected Toxicities Including Skin Rashes and Diarrhea(Up to 5 years)
Overall Survival(Time from the date of registration to last reported date of survival, assessed up to 5 years)

Investigators

Sponsor

National Cancer Institute (NCI)

Sponsor Class

Nih

Responsible Party

Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Completed

Phase 2

AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer

NCT00638937National Cancer Institute (NCI)37

Completed

Phase 2

NCT00513435National Cancer Institute (NCI)9

Completed

Phase 2

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic CancerAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer

NCT00735917National Cancer Institute (NCI)19

Completed

Phase 2

Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionAdenocarcinoma of the StomachRecurrent Gastric CancerStage III Gastric CancerStage III Esophageal CancerStage IV Esophageal CancerStage IV Gastric Cancer

NCT00607594National Cancer Institute (NCI)21

Completed

Phase 2

AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaEndometrial Stromal SarcomaDermatofibrosarcoma ProtuberansAdult FibrosarcomaAdult LeiomyosarcomaAdult LiposarcomaAdult Malignant Fibrous HistiocytomaAdult RhabdomyosarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Uterine SarcomaStage IV Adult Soft Tissue SarcomaStage IV Uterine SarcomaUterine CarcinosarcomaUterine Leiomyosarcoma

NCT00659360National Cancer Institute (NCI)17